Company Description
Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe.
It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries.
The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio.
The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index.
Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
| Country | United States |
| Founded | 1986 |
| Industry | Asset Management |
| Sector | Financials |
| CEO | Dr. Daniel R. Omstead M.S, Ph.D. |
Contact Details
Address: 1900 Market Street, Suite 200 Philadelphia, Pennsylvania 19103 United States | |
| Phone | (617) 772-8515 |
Stock Details
| Ticker Symbol | HQH |
| Exchange | NYSE |
| Reporting Currency | USD |
| CIK Code | 0000805267 |
| CUSIP Number | 87911J103 |
| ISIN Number | US87911J1034 |
| Employer ID | 04-6564285 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel R. Omstead M.S, Ph.D. | Portfolio Manager |
| Dr. Jason C. Akus M.B.A., M.D., MBA | Vice President of Research and Portfolio Manager |
| Christopher F. Brinzey MBA | Senior Vice President of Research and Portfolio Manager |
| Dr. Frank T. Gentile Ph.D. | Senior Vice President of Research and Portfolio Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 29, 2024 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 12, 2023 | N-CEN | Filing |
| Dec 11, 2023 | N-CSR | Filing |
| Nov 15, 2023 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| Oct 5, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 4, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |